Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CMRX

CMRX - Chimerix Inc Stock Price, Fair Value and News

$8.54 
Market Closed

Price Targets

CMRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CMRX Price Action

Last 7 days

0.1%

Last 30 days

0.7%

Last 90 days

140.6%

Trailing 12 Months

848.9%

CMRX RSI Chart

CMRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CMRX Valuation

Market Cap

801.1M

Price/Earnings (Trailing)

-9.06

Price/Sales (Trailing)

3.7K

EV/EBITDA

-9.61

Price/Free Cashflow

-10.64

CMRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

CMRX Fundamentals

CMRX Revenue

CMRX Earnings

CMRX Profitability

Free Cashflow Yield

-9.4%

CMRX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240288.0K252.0K216.0K
202325.4M17.1M8.7M324.0K
20229.9M17.9M25.9M33.8M
20215.6M4.6M3.1M2.0M
202011.4M11.4M11.0M5.4M
20198.8M9.0M10.6M12.5M
20184.2M4.7M4.2M7.2M
20175.6M4.4M4.6M4.5M
201610.8M8.4M6.8M5.7M
20154.5M7.7M8.8M10.8M
20143.4M3.5M3.8M4.0M
201332.4M27.0M7.1M4.4M
201217.5M22.9M28.3M33.7M
201100012.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Chimerix Inc

CMRX
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
 CEO
 WEBSITEchimerix.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES89

Chimerix Inc Frequently Asked Questions

CMRX is the stock ticker symbol of Chimerix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Apr 21 2025, market cap of Chimerix Inc is 801.08 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CMRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether CMRX is over valued or under valued. Whether Chimerix Inc is cheap or expensive depends on the assumptions which impact Chimerix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CMRX.

As of Mon Apr 21 2025, CMRX's PE ratio (Price to Earnings) is -9.06 and Price to Sales (PS) ratio is 3.71 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CMRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Chimerix Inc has provided -0.14 (multiply by 100 for percentage) rate of return.